Abstracts tagged "osteoporosis"

Abstract Number: 2621 • ACR Convergence 2025
Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
MAXIME AUROUX¹, MERCIER-GUERY Alexandre¹, PIOT Anne², MERLE Blandine³, PRORIOL Mathilde¹, FONTANGES Elisabeth¹, DUVERT Florence¹, Eric LESPESSAILLES⁴ and CHAPURLAT Roland¹, ¹Hospices Civils de Lyon, LYON, France, ²Centre Hospitalier Lucien Hussel, VIENNE, France, ³INSERM U¹⁰³³, LYON, France, ⁴University Hospital of Orléans, Orleans, France
Background/Purpose: Erosive hand osteoarthritis (ErHOA) is a severe form of hand osteoarthritis (HOA) characterized by greater inflammation and higher burden of disease. In this more…
Abstract Number: 2111 • ACR Convergence 2025
Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
Edward Li¹, Rebecca McTavish², Fatemeh Mirzayeh fashami², Sarah Kane² and Marion Schauf³, ¹Sandoz Inc., West Princeton, NJ, ²EVERSANA, Burlington, ON, Canada, ³Sandoz International GmbH, Holzkirchen, Bayern, Germany
Background/Purpose: Post-menopausal osteoporosis (PMO) significantly increases the risk of fractures in women, necessitating effective treatment strategies. The introduction of biosimilar denosumab offers the opportunity to…
Abstract Number: 0384 • ACR Convergence 2025
Hip Fracture Hospitalization Trends in Osteoporotic Patients (2016–2022): National Data Insights
Simran Bhimani¹, Anand Reddy Maligireddy², Sameer Bhimani³ and Birju Bhatt⁴, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center GME, Scarnton, PA, ³The Wright Center for GME, scranton, PA, ⁴Solara Health NJ, New Jersey, NJ
Background/Purpose: Hip fractures in patients with osteoporosis are a major contributor to morbidity, mortality, and healthcare costs. While classically associated with the oldest patients, emerging…
Abstract Number: 0340 • ACR Convergence 2025
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Chern Lee Choy¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
Abstract Number: 2596 • ACR Convergence 2025
Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach
Shiza sarfraz and Hassam Ali, East Carolina University Brody School of Medicine, Greenville, NC
Background/Purpose: Dual-energy X-ray absorptiometry (DXA) is the gold standard for diagnosing osteoporosis but is underutilized due to access, cost, and referral barriers. We aimed to…
Abstract Number: 2112 • ACR Convergence 2025
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…
Abstract Number: 0356 • ACR Convergence 2025
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Stephen Poos¹, Hoang Nguyen², Samuel Greenberg³, Marcus Lee², Heidi Roppelt¹ and Asha Patnaik², ¹Stony Brook Southampton Hospital, Southampton, NY, ²Stony Brook University Hospital, Stony Brook, NY, ³Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
Background/Purpose: Osteoporosis is under screened in men. The United States Preventive Services Task Force (USPSTF) does not publish guidelines for osteoporosis screening in men. Other…
Abstract Number: 0338 • ACR Convergence 2025
Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
Andriko Palmowski¹, Tobias Haugegaard², Ingiäld Hafstörm³, Henning Bliddal⁴, Judith Oldenkott⁵, Siegfried Wassenberg⁶, Ernest Choy⁷, John Kirwan⁸, Robin Christensen⁹, Maarten Boers¹⁰ and FRANK BUTTGEREIT¹¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Kopenhagen, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴The Parker Institute, Frederiksberg, Denmark, ⁵Charité, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁸University of Bristol, Bristol, United Kingdom, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹¹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: It is unclear to what extent low dose glucocorticoids (GCs) impact bone health in patients with rheumatoid arthritis (RA). RA leads to bone loss…
Abstract Number: 2595 • ACR Convergence 2025
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Edgar Wiebe¹, Claire-Felicia Liebich², Dörte Huscher³, Lien Meerkatt⁴, Andriko Palmowski⁵, Sandra Hermann¹, Burkhard Muche⁵, Zhivana Boyadzhieva², Gerhard Krönke⁶, Bernd Wolfarth² and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Physical exercise helps maintain bone mineral density (BMD), prevent falls, and reduce fracture risk. Strength and weight-bearing exercises are particularly effective. However, individuals with…
Abstract Number: 2110 • ACR Convergence 2025
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Edgar Wiebe¹, Kerstin Rubarth², Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche⁴, Gerhard Krönke⁵, Andriko Palmowski⁴ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures due to systemic inflammation and glucocorticoid (GC)…
Abstract Number: 0355 • ACR Convergence 2025
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Soukayna Baddi¹, Suarez Dimitri¹, Alexis Ruet¹, Theo Van Butsel¹, Damiano Cerasuolo¹, Jean-Matthieu L’Orphelin¹ and Anne-Christine Rat², ¹Caen University Hospital, Caen, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France
Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
Abstract Number: 0337 • ACR Convergence 2025
Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
Aakanksha Pitliya¹, Alexandra Georgiana Boc², Hema Latha Anam², Richard Oletsky², Dipabali Chaudhuri² and Rajesh Thirumaran², ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Osteoporosis remains underdiagnosed despite clear guidelines. As primary care physicians and trainees are key to preventive care, this quality improvement (QI) project aimed to…
Abstract Number: 2593 • ACR Convergence 2025
Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
Karel Pavelka¹, Frank Schneider², Deepak S³, Bracha Timan⁴, Hadas Barkay⁴ and Anton Buchner², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Teva GmbH, Ulm, Germany, ³Teva Pharma India Private Limited, Bangalore, India, ⁴Teva Pharmaceutical Industries Ltd., Netanya, Israel
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Biosimilarity of TVB-009 to US-licensed denosumab (US-denosumab) and EU-approved denosumab was…
Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].